| NCT ID | NCT06994169 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Lymphoma Academic Research Organisation |
| Condition | Large B-cell Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 250 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2026-03-27 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 250 participants in total. It began in 2025-12-01 with a primary completion date of 2026-03-27.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To date, more than 300 patients have been treated with Glofitamab in the Expanded Access Programme (EAP) in France. In this study, it is proposed to perform a retrospective analysis of some of these patients. The aim is to describe the efficacy and safety of Glofitamab in the largest reported real-world cohort, with an expected median follow-up of more than 9 months. Particular focus will be given to the relapsed or refractory chimeric antigen receptors-T (CAR-T) population to confirm the response rates (CRR: 35-39%) of Glofitamab in this population and to assess the optimal timing of therapy initiation \[8, 15\].
Eligibility Criteria
Inclusion Criteria: * patient enrolled in the French Glofitamab EAP for R/R DLBCL before 2024 November 1st, 2024 * patient who received at least Obinutuzumab pretreatment and one infusion of Glofitamab * adult patient * patient who is informed of the study and who did not oppose to their data collection Exclusion Criteria: * none
Contact & Investigator
Guillaume MANSON, MD
STUDY CHAIR
Lymphoma Study Association
Frequently Asked Questions
Who can join the NCT06994169 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Large B-cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06994169 currently recruiting?
Yes, NCT06994169 is actively recruiting participants. Contact the research team at glorel@lysarc.org for enrollment information.
Where is the NCT06994169 trial being conducted?
This trial is being conducted at Argenteuil, France, Avignon, France, Bayonne, France, Besançon, France and 11 additional locations.
Who is sponsoring the NCT06994169 clinical trial?
NCT06994169 is sponsored by The Lymphoma Academic Research Organisation. The principal investigator is Guillaume MANSON, MD at Lymphoma Study Association. The trial plans to enroll 250 participants.